[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prothena Corp (PRTA)

Prothena Corp (PRTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Prothena's Pipeline Credibility Hinges on Whether Milestone Revenue Repeats or Vanishes

Prothena Corporation (PRTA) is scheduled to report second-quarter 2026 earnings on August 3, 2026. The central question facing investors: can the clinical-stage biotechnology company sustain the momentum from its stunning first-quarter surprise, or will the stock revert to its historical pattern of losses? With shares trading at $8.12 and analysts projecting a return to negative earnings, this report will test whether PRTA's recent profitability marks a genuine inflection point or a temporary anomaly.

Prothena Corporation is a clinical-stage biotechnology company focused on developing novel antibody-based therapies for neurodegenerative diseases, including Alzheimer's and Parkinson's disease. The company's pipeline centers on protein misfolding disorders, with key...

Fundamentals

See More
  • Market Capitalization, $K 425,106
  • Shares Outstanding, K 52,353
  • Annual Sales, $ 9,680 K
  • Annual Income, $ -244,090 K
  • EBIT $ -119 M
  • EBITDA $ -115 M
  • 60-Month Beta -0.31
  • Price/Sales 45.47
  • Price/Cash Flow N/A
  • Price/Book 1.45

Options Overview Details

View History
  • Implied Volatility 136.64% (+70.74%)
  • Historical Volatility 44.25%
  • IV Percentile 78%
  • IV Rank 30.60%
  • IV High 339.95% on 11/19/25
  • IV Low 47.00% on 12/17/25
  • Expected Move (DTE 19) 0.57 (7.01%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 25
  • Volume Avg (30-Day) 238
  • Put/Call OI Ratio 0.57
  • Today's Open Interest 16,369
  • Open Int (30-Day) 15,987
  • Expected Range 7.55 to 8.69

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.39
  • Number of Estimates 3
  • High Estimate $-0.38
  • Low Estimate $-0.40
  • Prior Year $-1.86
  • Growth Rate Est. (year over year) +79.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.00 +1.50%
on 07/31/26
10.15 -20.00%
on 07/02/26
-1.67 (-17.06%)
since 06/30/26
3-Month
7.73 +5.05%
on 06/11/26
11.80 -31.19%
on 05/08/26
-2.94 (-26.58%)
since 04/30/26
52-Week
6.61 +22.84%
on 08/01/25
11.80 -31.19%
on 05/08/26
+1.24 (+18.02%)
since 07/30/25

Most Recent Stories

More News
Prothena's Pipeline Credibility Hinges on Whether Milestone Revenue Repeats or Vanishes

Barchart Research What to Expect from PRTA Earnings PRTA Generated July 31, 2026 Current Price $8.12 EPS Estimate $$-0.39 Consensus Rating Moderate Buy Average Move 2.61% Prothena's Pipeline Credibility...

PRTA : 8.12 (-3.45%)
Prothena to Report Second Quarter 2026 Financial Results on August 6

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 8.12 (-3.45%)
Prothena: Q1 Earnings Snapshot

Prothena: Q1 Earnings Snapshot

PRTA : 8.12 (-3.45%)
Prothena Reports First Quarter 2026 Financial Results and Business Highlights

Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates...

PRTA : 8.12 (-3.45%)
Prothena: Can Partners Carry the Narrative Through Another Year Without Internal Catalysts?

Barchart Research What to Expect from PRTA Earnings PRTA Generated May 6, 2026 Current Price $11.18 EPS Estimate $$-0.31 Consensus Rating Moderate Buy Average Move 2.81% Prothena: Can Partners Carry the...

PRTA : 8.12 (-3.45%)
Prothena to Report First Quarter 2026 Financial Results on May 7

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 8.12 (-3.45%)
Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy

Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy 1-3 Coramitug is being evaluated by...

PRTA : 8.12 (-3.45%)
Prothena Announces Leadership Team Updates

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced updates...

PRTA : 8.12 (-3.45%)
Prothena Partners Present Data Supporting Next Generation Treatments for Parkinson’s and Alzheimer’s Disease at AD/PD™ 2026

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced partner...

PRTA : 8.12 (-3.45%)
Prothena Announces Achievement of $50 Million Clinical Milestone Payment from Novo Nordisk Related to Ongoing Phase 3 Clinical Trial for Coramitug (Formerly PRX004) in ATTR Amyloidosis with Cardiomyopathy

Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy 1-3 Prothena has now earned $150 million...

PRTA : 8.12 (-3.45%)

Business Summary

Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis...

See More

Key Turning Points

3rd Resistance Point 8.93
2nd Resistance Point 8.72
1st Resistance Point 8.42
Last Price 8.12
1st Support Level 7.91
2nd Support Level 7.70
3rd Support Level 7.40

See More

52-Week High 11.80
Fibonacci 61.8% 9.82
Fibonacci 50% 9.20
Fibonacci 38.2% 8.59
Last Price 8.12
52-Week Low 6.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.